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     Malignant Hyperthermia (MH) is 
considered a pharmacogenetic disorder 
as it is an autosomal dominant disorder 
activated by the introduction of certain 
anesthetic agents solely or in 
conjunction with a neuromuscular 
blocker known as succinylcholine 
(Stratman, Flynn, & Hatton, 2009). 
Those genetically susceptible have a 
defect of the ryanodine receptor (RYR 
1), which encodes for the calcium 
channel on the sarcoplasmic reticulum 
of skeletal muscle cells. Once triggered 
by anesthesia agents, there is an 
exaggerated release of calcium resulting 
in a cascade of potentially lethal 
reactions. Uncontrolled increase in 
calcium stimulates actin and myosin to 
produce prolonged muscle contractions 
leading to accelerated adenosine 
triphosphate (ATP) depletion; oxygen 
consumption; glucose metabolism; 
lactate, carbon dioxide, and heat 
production. Consequently, acidosis, 
hyperthermia, and dangerously low ATP 
levels ensue thus causing the 
sarcolemma of the muscle cells to 
become damaged, cell death occurs, and 
intracellular contents such as 
magnesium, potassium, phosphate, and 
myoglobin are leaked systemically. The 
domino effect described places the 
patient in a hyper-metabolic state with 
potential for multiple organ damage and 
failure (Stratman et al., 2009). 
    Malignant hyperthermia is a rare and 
fatal disorder that can be challenging to 
detect and treat. Due to the low incidence 
of MH events, medical personnel are 
often not familiar and/or confident in the 
management of such an event. Therefore, 
it is the responsibility of the healthcare 
team to familiarize themselves with the 
disorder, the signs and symptoms, 
expected treatments, and evaluation of 
successful intervention. A study was 
done in the Midwest with all surgical  
personnel being placed in various 
simulations that were set to resemble a 
malignant hyperthermia crisis. The staff 
was educated on the disorder, simulation 
was completed, and all members were 
debriefed. The findings produced 
protocols and exercises that are done on 
a monthly basis to ensure all parties of 
the OR team are prepared for MH if it 
should arise. One recommendation that 
was vital to the teams was assigning each 
person with a specific task in order to 
accomplish all the interventions needed 
to safely care for a MH patient. For 
example, multiple members needed to 
dilute dantrolene as this can be a tedious 
step, another cooled the patient with ice, 
another documented the event, etc. 
(Cain, Reiss, Gettrust, & Novalija, 2014). 
PACU and ICU nurses also need to be 
educated as many signs and symptoms 
of MH may not present in the OR but in 
the PACU or critical care units (Barnes, 
Stowell, Bulger, Langton, & Pollock, 
2015). Nurses need to provide education 
for the patients and families of those 
whom have suffered with MH, assuring 
they understand how critical this 
disorder can be and how pertinent it is 
that they allow future anesthesia teams 
know of their susceptibility to the deadly 
disorder.  
 
      Surgeries are common, everyday 
procedures within the walls of America’s 
hospitals. According to Orser, Mazer, and 
Baker (2008), more than forty million 
patients in North America are given 
anesthetics annually. One of the major 
complications of anesthesia is malignant 
hyperthermia: a hyper-metabolic state 
that affects skeletal muscles. If left 
uncontrolled, malignant hyperthermia 
can cause multiple reactions within the 
body leading to metabolic and 
respiratory acidosis, cardiac 
dysrhythmias, kidney failure, 
coagulopathy, neurologic injury, and 
ultimately death (Seifert, Wahr, Pace, 
Cochrane, & Bagnola 2014). The 
incidence of this condition is estimated to 
be 1:15,000 in children and 1:20,000-
50,000 in adults (Redmond, 2001). 
Although considered a rare event, the 
mortality rate of malignant hyperthermia 
was eighty percent in 1960 and has 
steadily declined to less than ten percent 
by 1980 (Saleh, 1992). The concern, 
however, revolves around the facts that 
malignant hyperthermia is a hereditary 
condition that is difficult to screen for 
prior to the administration of anesthesia, 
and it occurs in every country and race, 
male and female, child and adult 
(Donnelly, 1994). Prompt intervention is 
crucial and can adequately impede the 
progression of this heightened metabolic 
state, yet, delayed action will quickly 
increase risk of death (Redmond, 2001). 
Therefore, continued education in 
regards to the pathophysiology of 
malignant hyperthermia will aid the 
surgical team in identifying risk factors, 
recognizing early signs, and interceding 
appropriately to protect patients from a 
potentially life-threatening reaction. 
    Meanwhile, the hyper-metabolic state 
perpetuates the rise in body temperature 
potentiating the risk for coagulation 
disorders such as disseminated 
intravascular coagulopathy and neurologic 
damage (Dirksen, Van Wicklin, Mashman, 
Neiderer, Merritt, 2013). However, the 
pathophysiology of MH can be significant 
in a positive way as it identifies what 
interventions will be effective in hindering 
the devastating pathway from continuing. 
For example, understanding the genetic 
origin of MH has led to genetic testing to 
identify those susceptible, knowledge of 
the sustained muscle contraction that 
occurs and begins the lethal progression 
has led to the use of dantrolene, a muscle 
relaxant, as the first-line treatment 
(Stratman et al., 2009), and the awareness 
of the systemic effects have led to 
numerous interventions to prevent a 
secondary injury (Dirksen et al., 2013). 
Therefore, understanding the 
pathophysiology of MH can help direct the 
perioperative team to prompt recognition 
and appropriate treatment of such a  
destructive disorder.  
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 Late signs can occur hours after 
exposure and are associated with 
mottled skin, disseminated intravascular 
coagulation, rhabdomyolysis, 
myoglobinuria, renal failure, respiratory 
and metabolic acidosis, and 
hyperthermia. Once hyperthermia sets 
in, shock and lethal arrhythmias can 
occur as quickly as twenty minutes due 
to oxygen consumption that is two to 
three times the normal rate of 
consumption (Stratman et al., 2009). All 
in all, the longer the disorder has to 
disturb the body’s homeostasis, the 
harder it is to combat. Early detection is 
paramount when dealing with malignant 
hyperthermia. 
  
     A 22 year old male presented to a 
military hospital after being injured by an 
improvised explosive device. He 
presented with a penetrating injury to his 
left thigh; radiological findings confirmed 
a left femur fracture. The patient was 
conscious and able to answer questions; 
he denied any allergies or past medical 
history. The man was prepared for 
surgery and given ketamine, 50 mg; 
etomidate, 30 mg; and succhinylcholine, 
120mg for rapid sequence intubation. 
Post-intubation vitals are as follows: 
blood pressure (BP) 115/60 mmHg; 
heart rate (HR) 90/min; arterial oxygen 
saturation (Sao2) 100%; end tidal carbon 
dioxide (ETCO2) 42 mmHg;  
temperature 98.6 degrees F. General 
anesthesia was maintained with 
sevoflurane. Total operative time was 
two hours with no complications.  
 Case Study 
However, upon completion, the BP was 
118/42; HR 106; Sao2 100%, ETCO2 65; 
and temp 100.4F. Pain medicine was given 
for increased heart rate yet fifteen minutes 
later the ETCO2 was 90, BP 140/78; HR 
110, temp 100.6. Hyperventilation was 
initiated to reduce ETCO2, and the 
anesthesia machine was inspected but no 
malfunction found. Concurrently, severe 
bilateral masseter muscle contractions and 
increased abdominal muscle rigidity were 
noted. The temperature climbed to 100.9F, 
labs were sent revealing hyperkalemia and 
a diagnosis of MH was made. The patient 
was then given dantrolene, 2.5mg/kg. Once 
the dantrolene bolus was given, muscular 
rigidity disappeared. Twenty minutes 
following bolus, ETCO2 was 35 and 
temperature was 100.5F, all other vital 
signs were stable. Seventy minutes after 
treatment, the patient was completely 
stable and was transported to another 
facility (Banet, Weatherwax, Spence, Perry, 
Muldoon & Capacchione, 2013). 
    Unfortunately, other diseases such as 
thyroid storm, heat stroke, 
pheochromocytoma, cocaine overdose, 
etc. can present in phenotypically similar 
ways as MH making timely diagnosis a 
challenge. Moreover, many genetically 
susceptible patients undergoing general 
anesthesia are unaware of their genetic 
defect; it is likely there will be no 
forewarning of this rapidly debilitating 
disorder. Therefore, detection of the 
signs and symptoms of malignant 
hyperthermia is imperative for the 
healthcare team in order to improve 
patient survival. The signs and symptoms 
for MH can be classified as either early or 
late. Typically, the earliest signs can 
occur within minutes of exposure and 
include: increased end tidal carbon 
dioxide, tachycardia, and contraction of 
the masseter muscle of the jaw. Other 
early signs are tachypnea, generalized 
muscle rigidity, cardiac arrhythmias, and 
electrolyte imbalances.  
Conclusion 
      Malignant hyperthermia is a 
complex, life-threatening crisis that 
presents multiple challenges yet can 
be successfully impeded with rapid 
and proper treatment. Continued  
education is essential for early 
detection, educated planning, swift 
implementation, and proficient  
evaluation of an MH event. Thorough 
pre-operative assessments, strong 
intra-operative knowledge, and 
efficient interdisciplinary roles will 
only bolster the fight against MH and 
ensure significant reduction in 
morbidity and mortality (Stratman et 
al., 2009). 
Signs and Symptoms 
